Specifically, mutations at 12 residues in TET2 that co‐occur in solid tumors are reported in myeloid malignancies no < 4 times, with mutations at residues 544, 550, 1380, and 1516 being particularly recurrent in myeloid disease (Table 1, Figure 3) [16]. Here, TET2 is linked to myeloid neoplasm.